Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)
Status:
Terminated
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
NNIPPS is a clinical trial of riluzole (a drug previously shown to slow down the rate of
progression og amyotrophic lateral sclerosis-ALS; Lou Gehrig's disease) involving nearly 800
people diagnosed with the 'parkinson plus' syndromes of multiple system atrophy (MSA) and
progressive supranuclear plasy (PSP). In addition to showing whether riluzole is helpful in
MSA and PSP, NNIPPS will improve criteria for making an accurate and early diagnosis, for
assessing the rate of progression, and will advance understanding of the biology of these
disabling and progressive neurodegenerative diseases.
Phase:
Phase 3
Details
Lead Sponsor:
King's College London
Collaborators:
Assistance Publique - Hôpitaux de Paris Aventis Pharmaceuticals University of Ulm